When the predictive power of all of these genes was tested on an ICI-treated melanoma patient cohort, 11 out of the 13 in vitro stable (containing IRGs SOX4, DEK, and HSPA1B) and AQP1 and CDCA4 in vivo stable DEGs were differentially expressed in the tumors of ICI responder melanoma patients. This evidence concerns the gene HSPA1B and melanoma.